James E. Wagner Cultivation Corporation
JWCAF
Other OTC0.00
USD
- -
- -
ISIN
CA47031P1080
CUSIP
47031P108
Return %
Stock
S&P500
1Y
0.00
26.53
3Y
900.00
76.60
5Y
-99.67
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Nathaniel Woodworth
- Full Time Employees
- 160
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 530 Trillium Drive Kitchener ON Canada N2R 1J4
- IPO Date
- Jun 25, 2018
- Website
- jwc.ca
- Similar Companies
- Business
- James E. Wagner Cultivation Corporation James E. Wagner Cultivation Corporation (JWCAF), through its subsidiary James E. Wagner Cultivation Ltd., engages in the cultivation and sale of medical cannabis in Canada; the company produces clean, consistent cannabis products utilizing a proprietary aeroponic platform named GrowthSTORM, which enhances cannabinoid concentration, optimizes yield through precise environmental controls including HVAC systems for humidity and temperature, and minimizes exposure to insects and disease; offerings include high-THC premium flower, single-origin derivatives, and new cultivars such as hash products developed post-restructuring, with an annual production capacity of approximately 7,000 kilograms from 114,000 square feet of licensed indoor facilities featuring JWC 1 and JWC 2 sites. Founded in 2007 and headquartered at 530 Trillium Drive in Kitchener, Ontario, the company targets medical cannabis patients and recreational markets primarily within Canada, leveraging partnerships for genetics access, distribution, sales, and quality assurance including past collaborations with Canopy Growth, MediPharm Labs, Conestoga College, and a licensing agreement for GrowthSTORM technology with Wellness Farms; it holds Health Canada licenses for cultivation, processing, and cannabis oil production across its operations. In recent major developments, Trichome Financial Corp. acquired the company's business and assets in 2020 through a court-approved restructuring process under the Companies' Creditors Arrangement Act for approximately C$13-16 million free of prior liabilities including C$19 million in debts, with Trichome's subsidiary Trichome JWC Acquisition Corp. securing replacement Health Canada licenses to continue operations, introducing new genetics, reducing staff by 40% to 107 employees for annual savings of C$3 million, and projecting C$22-24 million in 2021 fiscal revenue from 5,700 kilograms of flower; the company ceased direct-to-patient sales by April 30, 2021, shifting to an alternate sales model while selling subsidiary Sublime Culture Inc. to an undisclosed buyer; as of recent profiles, it maintains a reduced workforce of five employees focused on core aeroponics-based production amid ongoing OTC trading.